Market Cap 93.17M
Revenue (ttm) 90,000.00
Net Income (ttm) -46.89M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -52,100.00%
Debt to Equity Ratio 0.00
Volume 4,523,500
Avg Vol 14,653,540
Day's Range N/A - N/A
Shares Out 346.23M
Stochastic %K 38%
Beta 7.46
Analysts Hold
Price Target N/A

Company Profile

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety diso...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 61 4 0984 0786
Address:
8 Century Circuit, Suite 105 Norwest, Sydney, Australia
Neurogirl
Neurogirl Feb. 16 at 4:34 AM
$IXHL I went to 10 websites out of the 20 locations listed on clinical trials website. 10 different clinical research websites and none of them had any current or future studies listed for OSA trials. I don’t know what that means .
1 · Reply
qfcjhn
qfcjhn Feb. 16 at 3:33 AM
$IXHL Experience is about making mistakes, accepting them, learning, and continuing to acquire knowledge. When you start from scratch, you have the advantage of being open-minded!
0 · Reply
BullButter23
BullButter23 Feb. 16 at 2:18 AM
$IXHL Been down the rabbit hole again, just thinking out loud here. 👇 1. We know that P2 is complete however the status of the trial on clinical http://trials.gov is “active not recruiting”. Don’t they say “completed” at the completion each phase, not just on P3? 2. Im finding that it is NOT a legal requirement to release P2 minutes to shareholders. 3. I’m not saying that P3 has started, but I’m not saying that it hasn’t either. I do find it interesting that companies “can sometimes maintain confidentiality for proprietary reasons, but only if they are not actively trading their own stock or making other public statements that would be made misleading by omission.” Could it be that the silence from IXHL has been because of a proprietary threat, like waiting on a patent or a licensing agreement? Lastly, “enrolling the first subject in a clinical trial acts as a public disclosure.” IHL-42X status shows “active, not recruiting”, so IMO, we’ve been informed. Just some food for thought.
4 · Reply
Smug_Vortex
Smug_Vortex Feb. 16 at 1:50 AM
$IXHL Holy shit, I’ve never seen a post this elaborate on ST. You’re either deeply invested here or jacked to the tits on amphetamines. Either way, bravo for having more to say than the usual rocket and moon bullshit. 👏👏👏
1 · Reply
happyDaddy8
happyDaddy8 Feb. 16 at 1:10 AM
$IXHL I wouldn't care if it did RS at . 75
1 · Reply
happyDaddy8
happyDaddy8 Feb. 16 at 1:09 AM
$IXHL anyone think we have a chance at . 40 before RS
0 · Reply
Seamlessmingler
Seamlessmingler Feb. 16 at 1:00 AM
$IXHL I just replied to a post before and maybe this wont get read by someone who could make a bit of sence with the situation regards to, talks , MNPI , the point where they more from discussions to a letter of intent. Basicly whats the rules hoes its it work in IXHLs case?
0 · Reply
Jmb67
Jmb67 Feb. 16 at 12:51 AM
$IXHL What indicators support the bullish case?
1 · Reply
Clutch_shot
Clutch_shot Feb. 16 at 12:29 AM
0 · Reply
Amccorrie
Amccorrie Feb. 15 at 10:53 PM
$IXHL Not seem this really mentioned anywhere specifically so just putting it out there… In one of Joel’s recent interviews he said the following: We can run trials more efficiently and access the FDA via Project Orbis and other international collaboration pathways. Purely curious at his specific words here with “Access the FDA via Project Orbis and other international collaboration pathways”. Project Orbis is an Oncology Framework providing early access to other countries and regulators for drugs prior to FDA approval. Now Joel doesn’t currently have an oncology drug so why mention it? Are they exploring similar processes for other drugs. Moving to Dubai and PSX-001 being trialed internationally. I find this extremely interesting as it doesn’t seem relevant at all with what we know currently but is he trying to show us his next steps and bigger picture. This combined with the silence, FDA fast track and no EOP2’s yet have me wondering what’s going to be coming up this year?
3 · Reply
Latest News on IXHL
Clarion Clinics Open for Psychedelic-Assisted Treatments

Feb 1, 2024, 7:30 AM EST - 2 years ago

Clarion Clinics Open for Psychedelic-Assisted Treatments


Neurogirl
Neurogirl Feb. 16 at 4:34 AM
$IXHL I went to 10 websites out of the 20 locations listed on clinical trials website. 10 different clinical research websites and none of them had any current or future studies listed for OSA trials. I don’t know what that means .
1 · Reply
qfcjhn
qfcjhn Feb. 16 at 3:33 AM
$IXHL Experience is about making mistakes, accepting them, learning, and continuing to acquire knowledge. When you start from scratch, you have the advantage of being open-minded!
0 · Reply
BullButter23
BullButter23 Feb. 16 at 2:18 AM
$IXHL Been down the rabbit hole again, just thinking out loud here. 👇 1. We know that P2 is complete however the status of the trial on clinical http://trials.gov is “active not recruiting”. Don’t they say “completed” at the completion each phase, not just on P3? 2. Im finding that it is NOT a legal requirement to release P2 minutes to shareholders. 3. I’m not saying that P3 has started, but I’m not saying that it hasn’t either. I do find it interesting that companies “can sometimes maintain confidentiality for proprietary reasons, but only if they are not actively trading their own stock or making other public statements that would be made misleading by omission.” Could it be that the silence from IXHL has been because of a proprietary threat, like waiting on a patent or a licensing agreement? Lastly, “enrolling the first subject in a clinical trial acts as a public disclosure.” IHL-42X status shows “active, not recruiting”, so IMO, we’ve been informed. Just some food for thought.
4 · Reply
Smug_Vortex
Smug_Vortex Feb. 16 at 1:50 AM
$IXHL Holy shit, I’ve never seen a post this elaborate on ST. You’re either deeply invested here or jacked to the tits on amphetamines. Either way, bravo for having more to say than the usual rocket and moon bullshit. 👏👏👏
1 · Reply
happyDaddy8
happyDaddy8 Feb. 16 at 1:10 AM
$IXHL I wouldn't care if it did RS at . 75
1 · Reply
happyDaddy8
happyDaddy8 Feb. 16 at 1:09 AM
$IXHL anyone think we have a chance at . 40 before RS
0 · Reply
Seamlessmingler
Seamlessmingler Feb. 16 at 1:00 AM
$IXHL I just replied to a post before and maybe this wont get read by someone who could make a bit of sence with the situation regards to, talks , MNPI , the point where they more from discussions to a letter of intent. Basicly whats the rules hoes its it work in IXHLs case?
0 · Reply
Jmb67
Jmb67 Feb. 16 at 12:51 AM
$IXHL What indicators support the bullish case?
1 · Reply
Clutch_shot
Clutch_shot Feb. 16 at 12:29 AM
0 · Reply
Amccorrie
Amccorrie Feb. 15 at 10:53 PM
$IXHL Not seem this really mentioned anywhere specifically so just putting it out there… In one of Joel’s recent interviews he said the following: We can run trials more efficiently and access the FDA via Project Orbis and other international collaboration pathways. Purely curious at his specific words here with “Access the FDA via Project Orbis and other international collaboration pathways”. Project Orbis is an Oncology Framework providing early access to other countries and regulators for drugs prior to FDA approval. Now Joel doesn’t currently have an oncology drug so why mention it? Are they exploring similar processes for other drugs. Moving to Dubai and PSX-001 being trialed internationally. I find this extremely interesting as it doesn’t seem relevant at all with what we know currently but is he trying to show us his next steps and bigger picture. This combined with the silence, FDA fast track and no EOP2’s yet have me wondering what’s going to be coming up this year?
3 · Reply
Gettingchubby
Gettingchubby Feb. 15 at 10:50 PM
$IXHL I sometimes see people here suggesting that phase 3 maybe be in development right now because of the phase 2/3. In a recently posted interview from 3 weeks ago Joel stated "it's been a few months now without that asset (ihl-42x) being active in the clinic." I don't know when the actual interview was recorded, but as some have pointed out, it does appear he is sitting in Dubai during this interview. Somewhere within the last 4 months then. Joel also seems to really stress the importance of eop2 results and suggesting they're really waiting on the FDA to continue trial. The use of the buyback during what some of us thought to be a negotiation period, leaves very little room to suggest they're actively involved in an NDA of any kind. While my excitement for a catalyst big enough to reach compliance is pretty much gone, I'll keep holding because the company does seem to be taking the necessary steps to become a real player. Weekend rambling. Long term It's
2 · Reply
CaliCrypto
CaliCrypto Feb. 15 at 10:23 PM
0 · Reply
Rvvrn9
Rvvrn9 Feb. 15 at 9:41 PM
$IXHL It’s actually crazy when you step back and think about it. The same share price that convinced retail “nothing is happening” is the one that’s going to run on pure buyout speculation. The silence that scared people out will be the same silence they later call “obvious deal negotiations.” And the idea that management is just sitting around waiting for EOP2 notes while the compliance clock is ticking makes ZERO sense. A CEO with compensation tied to a change a “change of control event “ isn’t going to risk everything on paperwork timing while the stock drifts toward a reverse split. Like seriously??? A more realistic scenario is the EOP2 notes get announced with language that keeps Phase 3 optional, mentions strategic paths, and subtly leans toward partnership or acquisition. (Totally NDA compliant) That’s the kind of PR that doesn’t scream “buyout,” but it flips the narrative just enough. Suddenly retail isn’t pricing in a reverse split anymore… they’re pricing in a deal
1 · Reply
Rvvrn9
Rvvrn9 Feb. 15 at 9:14 PM
$IXHL If you assume the plan was always “go it alone” into Phase 3, then yeah… the silence, the structure changes, the lack of hiring, and the focus on EOP2 all look confusing. It feels complex because you’re trying to force today’s behavior into a solo development narrative. But go back to Joel’s own words in 2023. He said the structure was being simplified for a merger or sale. That was before the asset was fully derisked. Now look at where we are:…strong Phase 2 data, cleaner cap table, advisory board expansion, no Phase 3 infrastructure, no major financing, and continued silence around long term development plans and a compliance clock ticking like a time bomb. Through a “go it alone” lens, behavior looks INSANE Through a “prepare for sale” lens, it’s actually very clear as if it’s all coming to fruition. Same facts. Different lens. Completely different conclusion
2 · Reply
Rvvrn9
Rvvrn9 Feb. 15 at 9:01 PM
$IXHL It’s only complex when you take into consideration.,,,Retail is mostly inventing the “waiting on EOP2” narrative as a way to explain the silence. And no…it does not need to be disclosed to the public if it falls under NDA scrutiny. If you believe the intent was never to “go it alone” and the strategic path has always been “build on value and leverage for a maximum transactional outcome” Then a more behavior consistent interpretation is… The substance of EOP2 is already known, and the company is timing announcements around a strategic outcome, not waiting on paperwork to decide what to do. NFA But this is the only logical conclusion based on behavioral patterns, and the compliance clock.
0 · Reply
trt102967
trt102967 Feb. 15 at 8:38 PM
0 · Reply
CaliCrypto
CaliCrypto Feb. 15 at 8:37 PM
0 · Reply
RollTheDice369
RollTheDice369 Feb. 15 at 8:12 PM
$IXHL The issue is complex. Not only do we own shares, but so does the management. There is no way for them to profit from them. Of course, they receive their salaries, but their shares vest for a reason. Robert Clark receives huge bonuses in the event of a takeover, and his main remuneration depends on the sale of the company and the share price. They also had to pay tax on the vested shares. It seems to me that the company's current goal is EOP2 at any cost, not the stock price on the stock exchange. This is understandable. Joel emphasizes that they are also investors, but without good clinical data, nothing will come of it. None of them are selling their shares and they are extending their contracts. Someone like Robert Clark would not stay in a company that is a scam. The entire simplification of the financial structure is a textbook scenario prepared for the sale of the company, hence the multitude of theories – this is not surprising.
2 · Reply
nobodyyk
nobodyyk Feb. 15 at 7:51 PM
$IXHL insane hopium I’m actually shocked 😂😂😂😂😂😂😂😂
0 · Reply
4nJoy
4nJoy Feb. 15 at 7:24 PM
$IXHL @stockro1, well played! To amplify use a hand for visual heuristic to “See UR Investment” Use hand to create a simple 3D wireframe x-axis (middle finger horizontal inward) – People their Executives, Board, & Advisors. y-axis (index finger horizontal 90 degrees from middle) – Performance is neurobio platform w/assets improve patient outcomes, low risk/side effects, & unmet/underserved needs. z-axis (thumb vertical) – Promise is the potential for global market patient demand.
0 · Reply
stockro1
stockro1 Feb. 15 at 6:57 PM
$IXHL The drug. The people. The potential. Just a $93 million MC. 🤫
0 · Reply
qfcjhn
qfcjhn Feb. 15 at 6:38 PM
$IXHL Nothing spectacular is expected next week for short-term traders. Charts are valuable tools, as are Search EDGAR on the U.S. Securities and Exchange Commission and Fintel, for determining short-term and long-term trends.
1 · Reply